Hormone receptor–positive/ERBB2-negative (accounting for roughly 70% of cases), ERBB2-positive (15%–20%), and triple-negative breast cancer (15%), based on the expression of molecular markers including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (ERBB2). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.